A Phase 1 interventional study of Pimasertib and Pimasertib in Advanced Solid Tumors and Hepatocellular Carcinoma, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-23.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Carcinoma, Hepatocellular with a site in Japan — 17 open to participants now, 32 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Japan.
Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, this one is the 88th largest by enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2012, is one of 29 in phase 1, and was the 36th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →17 of the 115 studies in Carcinoma, Hepatocellular with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Australia and 11 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Boston Scientific Corporation · Sites in Japan
Ages 18+
Pfizer · Sites in Japan, United States, China and 2 more countries
Ages 18+
Zymeworks BC Inc. · Sites in Japan, United States, Ireland and 3 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 37 · Phase 3 34 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 182 across the 103 interventional studies, 563 across the 12 observational. Of the 76 that completed or were terminated, 43 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 115 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
12 of the studies in Carcinoma, Hepatocellular with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT03833700Eisai Co., Ltd.A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | 2027-03-31 |
| NCT06427941BeOne MedicinesA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC).
Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B). The dose will be increased from 45 mg twice a day (BID) with 3+3 cohort method up to the recommended phase 2 dose (RP2D) of pimasertib established as single agent in the global studies for each arm independently.
Part 2: The Maximum Tolerated Dose (MTD) defined in Part 1 will be confirmed in more subjects in Cohort A (N=18) and Cohort B (N=6) separately.
Following the recommendation by the Safety Monitoring Committee, Cohort B was discontinued due to hepatocellular carcinoma (HCC) and there will be no further enrollment of subjects to this cohort. This decision is based upon review of safety and efficacy information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort A: A or cytologically confirmed diagnosis of advanced solid tumors which is either after standard therapy for the disease or for which no effective standard therapy is available. Archived tumor tissue available or of tumor tissue needs to be performed.
Cohort B: A histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC) which is either refractory after standard therapy for the disease or for which no effective standard therapy is available. Archived tumor tissue available or biopsy of tumor tissue needs to be performed. Subjects with A.
Exclusion Criteria:
Hematological abnormality Cohort A: Hematological test abnormalities of \< 9.0 g/dL, \< 1.0*10\^9/L and count \< 100*10\^9/L.
Cohort B: Hematological test abnormalities of Hemoglobin \< 9.0 g/dL, Neutrophil count \< 1.0*10\^9/L, Platelet count \< 75*10\^9/L, subjects with hepatic encephalopathy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)
DLT defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0): any of following toxicities possibly/probably related to study drug: Any non-hematological toxicity of Grade 3 or higher (excluding Grade 3 asymptomatic rise in liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma-glutamyl transferase \[GGT\] reversible in 7 days for subjects with solid tumor and without liver involvement, or Grade 4 for subjects with HCC or with liver involvement; Grade 3 or 4 asymptomatic rise in creatinine phosphokinase (CPK) reversible in 7 days, deniable for myocardial infarction and rhabdomyolysis; Grade 3 vomiting/diarrhea encountered without optimal therapy). Any Grade 4 neutropenia \>5 days duration, any Grade 3 or above febrile neutropenia. Grade 4 thrombocytopenia \>1 day or Grade 3 with bleeding. Any treatment delay \>2 weeks due to drug-related adverse effects.
Time frame: During Treatment Cycle 1 (Day 1 to 21)
Number of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15
Data were not reported for "Part 1: Pimasertib 45 mg in HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15
Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Area Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours).
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15
Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Accumulation Ratio for AUC Racc(AUC) of Pimasertib
Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Accumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm
Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib
Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Accumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm
Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax).
Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Percentage of Subjects With Best Overall Response
Percentage of subjects with best overall response in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
Percentage of Subjects With Objective Response
Percentage of subjects with objective response (CR plus PR) according to RECIST Version 1.1 was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
Percentage of Subjects With Disease Control
Percentage of subjects with disease control (CR plus PR plus greater than 12 weeks SD) according to RECIST Version 1.1 was reported CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.
Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
First/last subject (informed consent): September 2012/April 2015. Last subject completed: April 2015.
| Milestone | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC) | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| Started | 4 | 9 | 6 | 5 | 2 |
| Completed | 4 | 9 | 6 | 5 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
DLT defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0): any of following toxicities possibly/probably related to study drug: Any non-hematological toxicity of Grade 3 or higher (excluding Grade 3 asymptomatic rise in liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma-glutamyl transferase \[GGT\] reversible in 7 days for subjects with solid tumor and without liver involvement, or Grade 4 for subjects with HCC or with liver involvement; Grade 3 or 4 asymptomatic rise in creatinine phosphokinase (CPK) reversible in 7 days, deniable for myocardial infarction and rhabdomyolysis; Grade 3 vomiting/diarrhea encountered without optimal therapy). Any Grade 4 neutropenia \>5 days duration, any Grade 3 or above febrile neutropenia. Grade 4 thrombocytopenia \>1 day or Grade 3 with bleeding. Any treatment delay \>2 weeks due to drug-related adverse effects.
| subjects | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT) | 0 | 0 | 2 | 1 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.
| subjects | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| TEAEs | 4 | 9 | 6 | 5 | 2 |
| Serious TEAEs | 2 | 2 | 2 | 2 | 0 |
| nanogram per milliliter (ng/mL) | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1 | 162.4 ± 113.1 | 222.1 ± 45.2 | 288.3 ± 52.1 | 167.6 ± 26.3 |
The summarized data was not available for this arm therefore individual data was presented.
| ng/mL | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 225 |
| Subject 2 | 281 |
Data were not reported for "Part 1: Pimasertib 45 mg in HCC" arm as there were no PK samples collected for this arm.
| ng/mL | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15 | 199.5 ± 58.9 | 231.6 ± 66.1 | 336.3 ± 30.8 | — |
The summarized data was not available for this arm therefore individual data was presented.
| ng/mL | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 320 |
| Subject 2 | 419 |
| hours | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1 | 2.450 (0.48 to 4.00) | 1.480 (0.48 to 7.98) | 1.710 (0.97 to 2.43) | 1.000 (0.95 to 2.57) |
The summarized data was not available for this arm therefore individual data was presented.
| hours | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 1.47 |
| Subject 2 | 1.92 |
Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| hours | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15 | 1.805 (1.00 to 2.48) | 1.910 (1.00 to 2.48) | 2.550 (1.50 to 5.88) | — |
The summarized data was not available for this arm therefore individual data was presented.
| hours | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 0.98 |
| Subject 2 | 0.95 |
| h*ng/mL | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1 | 703.0 ± 73.8 | 862.4 ± 42.8 | 1626.9 ± 43.6 | 911.4 ± 27.3 |
The summarized data was not available for this arm therefore individual data was presented.
| h*ng/mL | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 1754 |
| Subject 2 | 1430 |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours).
| h*ng/mL | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1 | 618.3 ± 86.1 | 857.4 ± 46.0 | 1629.3 ± 43.7 | 911.7 ± 27.2 |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.
| h*ng/mL | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 1761 |
| Subject 2 | 1431 |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| h*ng/mL | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15 | 1189.3 ± 73.6 | 1125.0 ± 62.1 | 2140.7 ± 37.6 | — |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.
| h*ng/mL | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 2250 |
| Subject 2 | 1687 |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
| hours | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1 | 3.480 (3.43 to 4.78) | 3.545 (2.77 to 5.24) | 3.935 (2.71 to 5.61) | 4.560 (3.27 to 11.5) |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.
| hours | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 5.68 |
| Subject 2 | 5.46 |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| hours | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15 | 4.235 (0.775 to 5.21) | 4.000 (3.13 to 5.71) | 5.530 (2.92 to 8.24) | — |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.
| hours | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 15.4 |
| Subject 2 | 5.41 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
| liter/hour (L/h) | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1 | 41.67 ± 80.5 | 48.17 ± 52.8 | 32.62 ± 54.6 | 32.19 ± 27.3 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. The summarized data was not available for this arm therefore individual data was presented.
| L/h | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 18.5 |
| Subject 2 | 23.7 |
Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| L/h | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15 | 25.24 ± 73.6 | 40.00 ± 62.1 | 28.02 ± 37.6 | — |
Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The summarized data was not available for this arm therefore individual data was presented.
| L/h | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 13.3 |
| Subject 2 | 17.8 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
| liters | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC |
|---|---|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1 | 231.2 ± 71.6 | 238.1 ± 46.7 | 169.8 ± 29.7 | 177.2 ± 15.9 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.
| liters | Part 1: Pimasertib 45 mg in HCC |
|---|---|
| Subject 1 | 152 |
| Subject 2 | 187 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| liters | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15 | 105.0 ± 161.1 | 233.9 ± 46.4 | 209.1 ± 10.6 | — |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.
| liters | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 297 |
| Subject 2 | 139 |
Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| ratio | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Accumulation Ratio for AUC Racc(AUC) of Pimasertib | 1.782 ± 4.2 | 1.382 ± 30.2 | 1.311 ± 51.5 | — |
Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15.
| ratio | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 2.43 |
| Subject 2 | 1.83 |
Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.
| ratio | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|
| Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib | 1.227 ± 38.3 | 0.8281 ± 65.5 | 1.215 ± 61.3 | — |
Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax).
| ratio | Part 1: Pimasertib 30 mg in HCC |
|---|---|
| Subject 1 | 1.50 |
| Subject 2 | 2.31 |
Percentage of subjects with best overall response in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of subjects | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 0 | 0 |
| PR | 0 | 42.9 | 0 | 0 | 0 |
| SD | 0 | 14.3 | 0 | 0 | 0 |
| PD | 66.7 | 42.9 | 75.0 | 75.0 | 50.0 |
| Not evaluable | 33.3 | 0 | 25.0 | 25.0 | 50.0 |
Percentage of subjects with objective response (CR plus PR) according to RECIST Version 1.1 was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of subjects | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| Percentage of Subjects With Objective Response | 0 | 42.9 | 0 | 0 | 0 |
Percentage of subjects with disease control (CR plus PR plus greater than 12 weeks SD) according to RECIST Version 1.1 was reported CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.
| percentage of subjects | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| Percentage of Subjects With Disease Control | 0 | 57.1 | 0 | 0 | 0 |
Collected over Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Pimasertib 30 mg in Solid Tumor | — | 2/4 (50%) | 4/4 (100%) |
| Part 1: Pimasertib 45 mg in Solid Tumor | — | 2/9 (22.2%) | 9/9 (100%) |
| Part 1: Pimasertib 60 mg in Solid Tumor | — | 2/6 (33.3%) | 6/6 (100%) |
| Part 1: Pimasertib 30 mg in HCC | — | 2/5 (40%) | 5/5 (100%) |
| Part 1: Pimasertib 45 mg in HCC | — | 0/2 (0%) | 2/2 (100%) |
| Event | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/4 | 0/9 | 0/6 | 2/5 | 0/2 |
| Disease progressionGeneral disorders | 1/4 | 0/9 | 0/6 | 0/5 | 0/2 |
| Liver disorderHepatobiliary disorders | 1/4 | 0/9 | 0/6 | 0/5 | 0/2 |
| General physical health deteriorationGeneral disorders | 0/4 | 0/9 | 1/6 | 0/5 | 0/2 |
| InfectionInfections and infestations | 0/4 | 0/9 | 1/6 | 0/5 | 0/2 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/4 | 0/9 | 1/6 | 0/5 | 0/2 |
| Jaundice cholestaticHepatobiliary disorders | 0/4 | 1/9 | 0/6 | 0/5 | 0/2 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 0/4 | 1/9 | 0/6 | 0/5 | 0/2 |
| Event | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/4 | 1/9 | 3/6 | 1/5 | 2/2 |
| Blood creatine phosphokinase increasedInvestigations | 4/4 | 6/9 | 5/6 | 2/5 | 0/2 |
| Retinal detachmentEye disorders | 3/4 | 6/9 | 5/6 | 3/5 | 1/2 |
| Vision blurredEye disorders | 3/4 | 6/9 | 5/6 | 3/5 | 1/2 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 1/4 | 6/9 | 3/6 | 4/5 | 0/2 |
| Aspartate aminotransferase increasedInvestigations | 3/4 | 5/9 | 1/6 | 2/5 | 1/2 |
| StomatitisGastrointestinal disorders | 1/4 | 1/9 | 4/6 | 2/5 | 0/2 |
| Oedema peripheralGeneral disorders | 1/4 | 5/9 | 4/6 | 0/5 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 5/9 | 3/6 | 3/5 | 1/2 |
| Retinal haemorrhageEye disorders | 0/4 | 2/9 | 0/6 | 0/5 | 1/2 |
Safety analysis set included all subjects who received at least one administration of pimasertib.
| Age, Continuous(years) | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC | Total |
|---|---|---|---|---|---|---|
| Mean | 62.3 ± 12.20 | 61.4 ± 10.63 | 61.5 ± 9.29 | 58.8 ± 13.63 | 56.5 ± 20.51 | 60.7 ± 11.0 |
| Sex: Female, Male(Participants) | Part 1: Pimasertib 30 mg in Solid Tumor | Part 1: Pimasertib 45 mg in Solid Tumor | Part 1: Pimasertib 60 mg in Solid Tumor | Part 1: Pimasertib 30 mg in HCC | Part 1: Pimasertib 45 mg in HCC | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 4 | 4 | 2 | 1 | 13 |
| Male | 2 | 5 | 2 | 3 | 1 | 13 |
Ran from Sep 2012 to primary completion in May 2015, 32 months.
Results were first posted in Mar 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib
Merck KGaA, Darmstadt, Germany →